The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that ...

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Blisters are small fluid-filled pockets that usually form as a result of friction, burns, or irritation, with tight shoes being one of the most common triggers. If you've ever found a painful bump ...

Of 153 cases of pemphigus and pemphigoid described by Lever, 1 30 cases of benign mucous-membrane pemphigus are discussed. In these 30 cases, 27 patients had oral lesions, and scarring occurred in 5.

Differentiation of PV from the other clinical variants of pemphigus, including pemphigus foliaceus, pemphigus erythematosus, pemphigus vegetans, and paraneoplastic pemphigus, is based primarily on ...

Bullous pemphigoid (BP) is the most common autoimmune blistering skin disease. 1 The term “pemphigoids” refers to a group of autoimmune bullous diseases characterized by subepidermal blistering. 1 ...

Bullous pemphigoid (BP) and pemphigus vulgaris (PV) share similar pathophysiology with venous thromboembolism (VTE) involving platelet activation, immune dysregulation, and systemic inflammation.

Results: The study involved 36 (56.3%) diagnosed with bullous pemphigoid (BP) and 28 (43.75%) with pemphigus vulgaris (PV). The average age in BP was 71 ± 8 and 52 ± 13 in PV. Laboratory findings ...